Publication:
Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: data from the Turkish Oncology Group

dc.contributor.coauthorUnal, Caglar
dc.contributor.coauthorAzizy, Abdulmunir
dc.contributor.coauthorKarabulut, Senem
dc.contributor.coauthorTastekin, Didem
dc.contributor.coauthorAkyildiz, Arif
dc.contributor.coauthorYasar, Serkan
dc.contributor.coauthorYalcin, Suayib
dc.contributor.coauthorCoban, Eyup
dc.contributor.coauthorEvrensel, Turkkan
dc.contributor.coauthorKalkan, Ziya
dc.contributor.coauthorOruc, Zeynep
dc.contributor.coauthorDerin, Sumeyra
dc.contributor.coauthorTurna, Zeynep Hande
dc.contributor.coauthorBayram, Dogan
dc.contributor.coauthorKos, Fahriye Tugba
dc.contributor.coauthorSendur, Mehmet Ali Nihat
dc.contributor.coauthorSever, Nadiye
dc.contributor.coauthorErcelep, Oezlem
dc.contributor.coauthorSeyyar, Mustafa
dc.contributor.coauthorKefeli, Umut
dc.contributor.coauthorUygun, Kazim
dc.contributor.coauthorOzcelik, Melike
dc.contributor.coauthorOn, Sercan
dc.contributor.coauthorSanli, Ulus Ali
dc.contributor.coauthorCanaslan, Kubra
dc.contributor.coauthorUnek, Ilkay Tuba
dc.contributor.coauthorYucel, Kadriye Bir
dc.contributor.coauthorOzdemir, Nuriye
dc.contributor.coauthorYazici, Ozan
dc.contributor.coauthorGuzel, Halil Goksel
dc.contributor.coauthorSalim, Derya Kivrak
dc.contributor.coauthorGoksu, Sema Sezgin
dc.contributor.coauthorTatli, Ali Murat
dc.contributor.coauthorOrdu, Cetin
dc.contributor.coauthorSelvi, Oguzhan
dc.contributor.coauthorSakin, Abdullah
dc.contributor.coauthorBuyukbayram, Mehmet Emin
dc.contributor.coauthorDursun, Bengu
dc.contributor.coauthorUrun, Yuksel
dc.contributor.coauthorArak, Haci
dc.contributor.coauthorAgdas, Gozde
dc.contributor.coauthorUgrakli, Muzaffer
dc.contributor.coauthorHendem, Engin
dc.contributor.coauthorEryilmaz, Melek Karakurt
dc.contributor.coauthorBilgin, Burak
dc.contributor.coauthorTopcu, Atakan
dc.contributor.coauthorSimsek, Melih
dc.contributor.coauthorBuyuksimsek, Mahmut
dc.contributor.coauthorAkay, Busra
dc.contributor.coauthorErdal, Gulcin Sahingoz
dc.contributor.coauthorKaratas, Fatih
dc.contributor.coauthorCaglayan, Melek
dc.contributor.coauthorKahvecioglu, Fatma Akdag
dc.contributor.coauthorDemirci, Ayse
dc.contributor.coauthorPaksoy, Nail
dc.contributor.coauthorCetin, Bulent
dc.contributor.coauthorGumus, Mahmut
dc.contributor.coauthorAk, Naziye
dc.contributor.coauthorAydinalp, Yasemin
dc.contributor.coauthorPaydas, Semra
dc.contributor.coauthorGuven, Deniz Can
dc.contributor.coauthorKilickap, Saadettin
dc.contributor.coauthorSaglam, Sezer
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.kuauthorAlan, Özkan
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2025-01-19T10:27:56Z
dc.date.issued2023
dc.description.abstractIntroduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).Methods: We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey.Results: The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second-and =third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment.Conclusions and Relevance: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue10
dc.description.openaccessGreen Published, gold
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThe authors sincerely thank Associate Prof. Phd Tomris Duymaz for her valuable contributions to this study.
dc.description.volume28
dc.identifier.doi10.1093/oncolo/oyad257
dc.identifier.eissn1549-490X
dc.identifier.issn1083-7159
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-8517408016
dc.identifier.urihttps://doi.org/10.1093/oncolo/oyad257
dc.identifier.urihttps://hdl.handle.net/20.500.14288/25641
dc.identifier.wos1063354900001
dc.keywordsCapecitabine
dc.keywordsCAPTEM
dc.keywordsNeuroendocrine neoplasia
dc.keywordsNeuroendocrine tumors
dc.keywordsTemozolomide
dc.language.isoeng
dc.publisherOxford Univ Press
dc.relation.grantnoThe authors sincerely thank Associate Prof. Phd Tomris Duymaz for her valuable contributions to this study.
dc.relation.ispartofOncologist
dc.subjectOncology
dc.titleEfficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: data from the Turkish Oncology Group
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAlan, Özkan
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR05219.pdf
Size:
4.38 MB
Format:
Adobe Portable Document Format